Tyra Biosciences, Inc.

NASDAQ: TYRA · Healthcare · Biotechnology

PublicHQ Carlsbad, CA · San DiegoCIK 0001863127Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 59DQ —GM —SS 53

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$119.9M

Employees

as of 2026-08-09

Market cap

$1.6B

as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$119.9M-$119.9M2025

Operating income-$132.8M-$132.8M2025

Total assets$282.6M$282.6M2025

Liabilities$23.4M$23.4M2025

Equity$259.2M$259.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Tyra Biosciences, Inc.’s financial profile?

Tyra Biosciences, Inc. earned -$119.9M in FY2025 net income.

Peers · Healthcare

Braveheart Bio, Inc.——Damora Therapeutics, Inc.——Generate Biomedicines, Inc.——Bicara Therapeutics Inc. Common Stock——First Tracks Biotherapeutics Inc——ArriVent BioPharma, Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOTodd Harris

SectorHealthcare

IndustryBiotechnology

HeadquartersCarlsbad, CA

ExchangeNASDAQ: TYRA

Employees87

IPO date2021-09-15

Latest filings

8-K2026-08-04 10-Q2026-08-04 8-K2026-06-02 8-K2026-05-13 10-Q2026-05-13 DEF 14A2026-04-17 8-K2026-04-17 8-K2026-04-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.